A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
一项针对HR阳性/HER2阴性晚期乳腺癌患者的帕博西尼联合他莫昔芬的3期研究(PATHWAY)
期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-024-00684-w
Noguchi, Emi; Yamanaka, Takashi; Mukai, Hirofumi; Yamamoto, Naohito; Chung, Chi-Feng; Lu, Yen-Shen; Chang, Dwan-Ying; Sohn, Joohyuk; Kim, Gun Min; Lee, Kyung-Hun; Lee, Soo-Chin; Iwasa, Tsutomu; Iwata, Hiroji; Watanabe, Kenichi; Jung, Kyung Hae; Tanabe, Yuko; Kang, Seok Yun; Yasojima, Hiroyuki; Aogi, Kenjiro; Tokunaga, Eriko; Sim, Sung Hoon; Yap, Yoon Sim; Matsumoto, Koji; Tseng, Ling-Ming; Umeyama, Yoshiko; Sudo, Kazuki; Kojima, Yuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Nakamura, Kenichi; Fujiwara, Yasuhiro; Tamura, Kenji; Yonemori, Kan